The gut microbiota alters energy homeostasis. In parallel, metformin regulates upper small
intestinal sodium glucose cotransporter-1 (SGLT1), but whether changes of the microbiota or …

OBJECTIVE To determine the longer-term effects of metformin treatment and behavioral
weight loss on gut microbiota and short-chain fatty acids (SCFAs). RESEARCH DESIGN …

Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the
mechanisms underlying the plasma glucose level-lowering effects of metformin (1, 1 …

The ratio of human to bacterial cells in the human body (microbiota) is around 1: 1. As a
result of co-evolution of the host mucosal immune system and the microbiota, both have …

Even though metformin is widely used to treat type2 diabetes, reducing glycaemia and body
weight, the mechanisms of action are still elusive. Recent studies have identified the …

Type 2 diabetes (T2D) is associated with dysbiosis of the gut microbiota, though diabetes
treatment regimens, including metformin, may confound the results. Forslund et al.(2015) …

The anti-hyperglycemic effect of metformin is believed to be caused by its direct action on
signaling processes in hepatocytes, leading to lower hepatic gluconeogenesis. Recently …

Gut microbiota contribute to host metabolic efficiency by increasing energy availability
through the fermentation of dietary fiber and production of short-chain fatty acids (SCFAs) in …

Background and aims: Obese and diabetic mice display enhanced intestinal permeability
and metabolic endotoxaemia that participate in the occurrence of metabolic disorders. Our …

Metformin is widely used in the treatment of type 2 diabetes (T2D), but its mechanism of
action is poorly defined. Recent evidence implicates the gut microbiota as a site of metformin …